Corresponding Author: Joshua M. Sharfstein, MD, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Room W1033F, Baltimore, MD 21205 (joshua.sharfstein@jhu.edu).
Published Online: March 9, 2020. doi:10.1001/jama.2020.3864
Conflict of Interest Disclosures: Dr Mello reported receiving grants from the Greenwall Foundation, a nonprofit foundation focused on bioethics. No other disclosures were reported.
Additional Information: Dr Sharfstein reported serving as Principal Deputy Commissioner of the US Food and Drug Administration from March 2009 to January 2011.
2.US Food and Drug Administration. Letter from RADM Denise M. Hinton, Chief Scientist, to Robert R. Redfield, Director, Centers for Disease Control and Prevention. March 2, 2020.
https://www.fda.gov/media/135763/download 5.Hellewell
J , Abbott
S , Gimma
A ,
et al; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts.
Lancet Glob Health. 2020;S2214-109X(20)30074-7. Published online February 28, 2020. doi:
10.1016/S2214-109X(20)30074-7PubMedGoogle Scholar 6.Caliendo
AM , Couturier
MR , Ginocchio
CC ,
et al; Infectious Diseases Society of America; the American Society for Microbiology; and the Pan-American Society for Clinical Virology. Maintaining life-saving testing for patients with infectious diseases: Infectious Diseases Society of America, American Society for Microbiology, and Pan American Society for Clinical Virology recommendations on the regulation of laboratory-developed tests.
Clin Infect Dis. 2016;63(2):151-154. doi:
10.1093/cid/ciw260PubMedGoogle ScholarCrossref